<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01503112</url>
  </required_header>
  <id_info>
    <org_study_id>11233581</org_study_id>
    <nct_id>NCT01503112</nct_id>
  </id_info>
  <brief_title>Predicting Response to Incretin Based Agents in Type 2 Diabetes</brief_title>
  <acronym>PRIBA</acronym>
  <official_title>Does Urinary C-peptide Creatinine Ratio Predict Response to Incretin Based Agents in Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Royal Devon and Exeter NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute for Health Research, United Kingdom</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Exeter</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Royal Devon and Exeter NHS Foundation Trust</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Type 2 diabetes is a major and rapidly increasing health problem worldwide. Keeping the blood
      glucose (sugar) from going too high helps prevent complications. Recently a number of new
      treatments (collectively called 'incretin based' treatments) to lower blood glucose have
      become available but response is very variable and it is difficult to predict which will work
      for an individual. The investigators want to see if we can identify whether the new
      treatments are likely to be effective for an individual patient. Identifying the right
      treatment would improve control and minimise the side-effects and costs from ineffective
      treatments. We will collect blood (for measures of blood glucose, insulin secretion and
      genetics information), urine (for a simple measurement of insulin secretion) and other
      clinical information (such as weight,age, duration of diabetes and medication) in people who
      are about to start these new 'incretin based' treatments and assess their response over the
      first 6 months of treatment. We will analyse this information to see if we can predict
      treatment response.

      Study Hypothesis:

      The investigators hypothesise that those who have low insulin secretion, as measured by post
      meal urine C-peptide Creatinine Ratio or blood C-peptide, will have poor blood glucose
      response to incretin based treatments.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2011</start_date>
  <completion_date type="Actual">April 2014</completion_date>
  <primary_completion_date type="Actual">April 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Glycaemic response (HbA1c change post treatment)</measure>
    <time_frame>6 months</time_frame>
    <description>Change in HbA1c over 6 months treatment (as a continuous variable and/or defined as binary response/non response). Our Primary analysis will be the relationship between insulin secretion (as measured by blood C-peptide or UCPCR) and glycaemic response. Secondary analysis will include examination of relationship between baseline weight, HbA1c, age, duration of diabetes, HOMA B, HOMA IR, autoantibody (GAD, IA2) status and glycaemic response. We will also examine the relationship between glycaemic response and polymorphisms in GLP-1R, TCF7L2, WFS1 and FOX01 genes.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Weight change over 6 months treatment</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">957</enrollment>
  <condition>Type2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Patients starting incretin treatments</arm_group_label>
    <description>Patients starting GLP-1 agonists or DPPIV inhibitors as part of their normal clinical care.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No intervention, observational study</intervention_name>
    <arm_group_label>Patients starting incretin treatments</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Extracted DNA, stored serum/plasma
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with type 2 Diabetes commencing DPP-IV inhibitors or GLP-1 agonsists in primary or
        secondary care in England
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  A clinical diagnosis of type 2 diabetes mellitus where the patient's clinician has
             determined the need for a DPP-IV inhibitor or GLP-1 analogue as a result of inadequate
             glycaemic control

          -  HbA1c &gt;= 58mmol/mol

        Exclusion Criteria:

          -  Treatment with DPP-IV inhibitors or GLP-1 analogues prior to study initiation (within
             the previous 3 months)

          -  Renal failure as shown by a eGFR (estimated glomerular filtration rate) less than 30
             mL/min/1.73m2
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrew T Hattersley</last_name>
    <role>Study Director</role>
    <affiliation>University of Exeter Medical School/Royal Devon and Exeter Hospital NHS Foundation Trust</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Angus Jones</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Exeter Medical School/Royal Devon and Exeter Hospital NHS Foundation Trust</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cornwall and Isles of Scilly NHS Primary Care Trust</name>
      <address>
        <city>Truro</city>
        <state>Cornwall</state>
        <zip>TR13HD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Devon NHS Trust</name>
      <address>
        <city>Barnstaple</city>
        <state>Devon</state>
        <zip>EX314JB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Devon and Exeter NHS Foundation Trust</name>
      <address>
        <city>Exeter</city>
        <state>Devon</state>
        <zip>EX25DW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Plymouth Hospitals NHS Trust</name>
      <address>
        <city>Plymouth</city>
        <state>Devon</state>
        <zip>PL68DH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Devon Healthcare NHS Foundation Trust</name>
      <address>
        <city>Torbay</city>
        <state>Devon</state>
        <zip>TQ27AA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Taunton and Somerset NHS Foundation Trust.</name>
      <address>
        <city>Taunton</city>
        <state>Somerset</state>
        <zip>BA228HR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yeovil Disctrict Hospital NHS Foundation Trust</name>
      <address>
        <city>Yeovil</city>
        <state>Somerset</state>
        <zip>BA21 4AT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Royal Bournmouth and Christchurch Hospitals NHS Trust</name>
      <address>
        <city>Bournmouth</city>
        <zip>BH7 7DW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Bristol NHS Trust</name>
      <address>
        <city>Bristol</city>
        <zip>BS10 5NB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ipswich Hospital NHS Trust</name>
      <address>
        <city>Ipswich</city>
        <zip>IP4 5PD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northampton General Hospital NHS Trust</name>
      <address>
        <city>Northampton</city>
        <zip>NN15BD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oxford Radcliffe Hospitals NHS Trust</name>
      <address>
        <city>Oxford</city>
        <zip>OX3 9DU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Portsmouth Hospitals NHS Trust</name>
      <address>
        <city>Portsmouth</city>
        <zip>PO6 3LY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Surrey and Sussex Healthcare NHS trust</name>
      <address>
        <city>Redhill</city>
        <zip>RH1 5RH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>East Sussex Healthcare NHS Trust</name>
      <address>
        <city>St Leonards-on-Sea</city>
        <zip>TN37 7RD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospitls North Staffordshire NHS Trust</name>
      <address>
        <city>Stoke on Trent</city>
        <zip>ST4 7LN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Warwickshire NHS Foundation Trust</name>
      <address>
        <city>Warwick</city>
        <zip>CV34 5BW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West Hertfordshire Hospitals NHS Trust</name>
      <address>
        <city>Watford</city>
        <zip>WD18 0HB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://www.diabetesgenes.org</url>
    <description>Research group website</description>
  </link>
  <results_reference>
    <citation>Jones AG, McDonald TJ, Shields BM, Hill AV, Hyde CJ, Knight BA, Hattersley AT; PRIBA Study Group. Markers of Î²-Cell Failure Predict Poor Glycemic Response to GLP-1 Receptor Agonist Therapy in Type 2 Diabetes. Diabetes Care. 2016 Feb;39(2):250-7. doi: 10.2337/dc15-0258. Epub 2015 Aug 4.</citation>
    <PMID>26242184</PMID>
  </results_reference>
  <results_reference>
    <citation>Dennis JM, Shields BM, Hill AV, Knight BA, McDonald TJ, Rodgers LR, Weedon MN, Henley WE, Sattar N, Holman RR, Pearson ER, Hattersley AT, Jones AG; MASTERMIND Consortium. Precision Medicine in Type 2 Diabetes: Clinical Markers of Insulin Resistance Are Associated With Altered Short- and Long-term Glycemic Response to DPP-4 Inhibitor Therapy. Diabetes Care. 2018 Apr;41(4):705-712. doi: 10.2337/dc17-1827. Epub 2018 Jan 31.</citation>
    <PMID>29386249</PMID>
  </results_reference>
  <results_reference>
    <citation>Jones AG, Shields BM, Hyde CJ, Henley WE, Hattersley AT. Identifying good responders to glucose lowering therapy in type 2 diabetes: implications for stratified medicine. PLoS One. 2014 Oct 23;9(10):e111235. doi: 10.1371/journal.pone.0111235. eCollection 2014.</citation>
    <PMID>25340784</PMID>
  </results_reference>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 30, 2011</study_first_submitted>
  <study_first_submitted_qc>December 30, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 2, 2012</study_first_posted>
  <last_update_submitted>April 17, 2018</last_update_submitted>
  <last_update_submitted_qc>April 17, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Royal Devon and Exeter NHS Foundation Trust</investigator_affiliation>
    <investigator_full_name>Angus Jones</investigator_full_name>
    <investigator_title>NIHR Doctoral Research Fellow</investigator_title>
  </responsible_party>
  <keyword>Glucagon-Like Peptide 1, DPP4 protein, Therapeutics, Hypoglycemic Agents, C-Peptide, Type 2 Diabetes Mellitus,</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Incretins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

